Analyst Reiterates Buy on Damora Therapeutics, Maintains $45 Price Target on Differentiated Clinical StrategyTip Ranks·17 hours agoDMRA+2.78%
Damora Therapeutics posts corporate deck on mutCALR-targeted therapies for myeloproliferative neoplasmsPUBT·1 day ago, 03:39 PMDMRA+2.78%
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate HighlightsUnusual Whales·1 day ago, 03:07 PMDMRA+2.78%
Damora Therapeutics starts Phase 1/1b CLARITY-101 trial of DMR-001 in mutant CALR-driven ET, myelofibrosisPUBT·Aug 5 at 07:03 AMDMRA+2.78%
Damora Therapeutics grants 451,000 inducement stock options at $28.99 per sharePUBT·Aug 3 at 03:01 PMDMRA+2.78%
This Damora Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mondaybenzinga_article·Jul 27 at 06:56 AMITG-5.93%BSP+3.91%
Damora Therapeutics: Buy Rating Reaffirmed on Differentiated ET/MF Candidate and $50 Price TargetTip Ranks·Jul 26 at 03:05 PMDMRA+2.78%
Damora Announces Redomestication from Delaware to Cayman IslandsUnusual Whales·Jul 19 at 08:01 AMDMRA+2.78%
Damora Therapeutics (DMRA) Joins Russell Indexes With Valuation Still Looking About RightSimplywall·Jul 6 at 11:06 PMDMRA+2.78%
Damora Therapeutics grants inducement stock options for 453,500 shares at USD 26.01 eachPUBT·Jul 1 at 03:01 PMDMRA+2.78%
RBC Capital Keeps Their Buy Rating on Damora Therapeutics (DMRA)Tip Ranks·Jun 30 at 06:05 AMDMRA+2.78%
